Thursday, July 27, 2023
Hummingbird Bioscience has announced a significant step in advancing clinical development by initiating two Phase IB clinical trials in Australia.
The focus of the trials will be on evaluating the activity of HMBD-001, a differentiated HER3-targeting antibody that specifically inhibits HER3 oncogenic signalling. The two patient groups being studied are those with squamous non-small cell lung carcinoma (sqNSCLC) and patients with genetic aberrations in HER3 signalling.
By collaborating with Omico, Hummingbird Bioscience gains access to the PrOSPeCT initiative and network in Australia. Omico's PrOSPeCT initiative will play a crucial role in accelerating the clinical development of HMBD-001 by providing patient referrals to the trials.
Collaborations between Hummingbird Bioscience and Omico represent a step forward in creating a more sustainable and research-led model of healthcare. Together, this partnership has the potential to contribute significantly to advancements in precision medicine and ultimately lead to better outcomes for cancer patients.